文献速递支持与姑息治疗

Umbralisib治疗复发或难治性慢性淋巴细胞白血病及淋巴瘤的首次人体1期剂量递增研究

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
PubMed 文献 · Lancet Oncol · 2018-02-20

该研究为开放标签、1期剂量递增首次人体试验,纳入90例复发或难治性慢性淋巴细胞白血病或淋巴瘤患者,评估新型PI3Kδ及酪蛋白激酶1ε抑制剂Umbralisib的安全性、最大耐受剂量与初步抗肿瘤活性。结果显示Umbralisib耐受性良好,安全谱与其他PI3Kδ抑制剂不同,结肠炎等自身免疫样毒性较少,并显示出初步疗效信号。

要点

  • Umbralisib在复发或难治性血液肿瘤中耐受性良好,并显示初步抗肿瘤活性。
  • 推荐2期剂量为微粒化制剂800 mg,最大耐受剂量为微粒化制剂1200 mg。
  • 90例患者中33例(37%)获得客观缓解。

核心结论

  • Umbralisib耐受性良好,在复发或难治性血液系统恶性肿瘤中显示初步活性。
  • 其1期安全性谱与其他PI3Kδ抑制剂不同,结肠炎等自身免疫样毒性发生较少。
  • 作者认为这些发现值得在该人群中进一步评估该药物。

研究设计与样本

  • 开放标签、1期、剂量递增、首次人体研究,在美国7家诊所开展。
  • 纳入年龄至少18岁、接受过至少1线既往治疗、具有可测量可评估病灶且器官功能足够的复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、B细胞或T细胞非霍奇金淋巴瘤或霍奇金淋巴瘤患者。
  • 2013年1月17日至2016年1月14日共入组并治疗90例患者,采用传统3+3设计进行剂量递增。
  • 主要终点为所有治疗患者中研究者评估的安全性、最大耐受剂量及药代动力学;次要终点包括客观缓解和缓解持续时间等初步抗肿瘤活性评估。

主要发现

  • 最常见的治疗中出现的不良事件(不论因果关系)为腹泻(39/90例,43%)、恶心(38例,42%)和疲乏(28例,31%)。
  • 最常见的3级或4级不良事件为中性粒细胞减少(12例,13%)、贫血(8例,9%)和血小板减少(6例,7%)。
  • 被认为至少可能与Umbralisib相关的严重不良事件发生于7例患者:肺炎3例(3%)、肺部感染1例(1%)、发热性中性粒细胞减少1例(1%)、结肠炎2例(2%),其中1例同时发生发热性中性粒细胞减少。
  • 90例入组患者中33例(37%)获得客观缓解。

关键数值与推荐

  • 最大耐受剂量为微粒化制剂1200 mg,推荐2期剂量为微粒化制剂800 mg。
  • 2例结肠炎均发生于推荐2期剂量以上。
  • 初始队列空腹状态下起始剂量50 mg,递增至100、200、400、800、1200和1800 mg;后续队列进食状态下微粒化制剂起始200 mg,递增至400、800、1200和1800 mg。
  • 2014年8月,仍在研究中的患者全部转为微粒化制剂800 mg,初始制剂停止给药。

临床怎么用

  • Umbralisib在复发或难治性慢性淋巴细胞白血病及淋巴瘤中显示可接受的安全性和初步活性,支持后续进一步临床评估。
  • 推荐2期剂量为微粒化制剂800 mg每日一次口服,2期及以上剂量需关注结肠炎等毒性。
  • 该药安全性谱与其他PI3Kδ抑制剂不同,自身免疫样毒性较少,可能为PI3Kδ抑制剂不耐受患者提供选择。

局限性

  • 本研究为1期、开放标签、剂量递增首次人体研究,样本量90例,主要目的是安全性及剂量确定。
  • 抗肿瘤活性为初步评估,未设对照,客观缓解由研究者评估。
  • 患者随访在停止治疗后即结束,缺乏长期疗效与安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Umbralisib (TGR-1202) is a novel next-generation inhibitor of phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ), which is structurally distinct from other PI3Kδ inhibitors and shows improved isoform selectivity. Umbralisib also uniquely inhibits casein kinase-1ε, a major regulator of protein translation. The aim of this first-in-human phase 1 study was to establish the safety and preliminary activity profile of umbralisib in patients with haematological malignancies. METHODS: We did an open-label, phase 1, dose-escalation study at seven clinics in the USA. We recruited patients aged at least 18 years with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma, B-cell and T-cell non-Hodgkin lymphoma, or Hodgkin's lymphoma, who had received one or more previous lines of therapy, with measurable and assessable disease, and adequate organ system function. Patients self-administered an umbralisib oral tablet once per day in 28-day cycles, with dose escalation done in a traditional 3 + 3 design to establish safety and determine the maximum tolerated dose. In initial cohorts, patients took umbralisib in a fasting state at a starting dose of 50 mg, increasing to 100, 200, 400, 800, 1200, and 1800 mg until the maximum tolerated dose was reached, or the maximal dose cohort was accrued without a dose-limiting toxicity. Subsequent cohorts self-administered a micronised formulation of umbralisib tablet in a fed state at an initial dose of 200 mg, increased in increments to 400, 800, 1200, and 1800 mg until the maximum tolerated dose or the maximal dose level was accrued. In August, 2014, all patients still on study were transitioned to 800 mg of the micronised formulation and dosing of the initial formulation was discontinued. The primary endpoints of the study were investigator-assessed safety in all treated patients (the safety population), the maximum tolerated dose, and the pharmacokinetics of umbralisib. Secondary endpoints included preliminary assessments of anti-cancer activity (objective responses and duration of response). Follow-up stopped for a patient once they discontinued therapy. This study has been completed and is registered with ClinicalTrials.gov, number NCT01767766. FINDINGS: Between Jan 17, 2013, and Jan 14, 2016, we enrolled and treated 90 patients with umbralisib. The median duration of treatment and follow-up was 4·7 cycles (IQR 2·0-14·0) or 133 days (IQR 55-335). The most common treatment-emergent adverse events irrespective of causality were diarrhoea (in 39 [43%] of 90 patients), nausea (38 [42%]), and fatigue (28 [31%]). The most common grade 3 or 4 adverse events were neutropenia (in 12 [13%] patients), anaemia (eight [9%]) and thrombocytopenia (six [7%]). Serious adverse events considered at least possibly related to umbralisib occurred in seven patients: pneumonia in three (3%) patients, lung infection in one (1%), febrile neutropenia in one (1%), and colitis in two (2%), one of whom also had febrile neutropenia. The maximum tolerated dose was 1200 mg of the micronised formulation, with 800 mg of this formulation selected as the recommended phase 2 dose. Both cases of colitis occurred at above the recommended phase 2 dose. 33 (37%) of the 90 patients enrolled had an objective response to treatment with umbralisib. INTERPRETATION: Umbralisib was well tolerated and showed preliminary signs of activity in patients with relapsed or refractory haematological malignancies. The safety profile of umbralisib in this phase 1 study was distinct from that of other PI3Kδ inhibitors, with fewer occurrences of autoimmune-like toxicities such as colitis. These findings warrant further evaluation of this agent in this setting. FUNDING: TG Therapeutics.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Burris HA, Flinn IW, Patel MR, et al. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018. PMID: 29475723. doi:10.1016/S1470-2045(18)30082-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。